Korbut Renata A, Adamek-Guzik Teresa
Katedra i Klinika Chorób Wewnetrznych, Medycyny Wsi Collegium Medicum, Uniwersytetu Jagiellońskiego, Kraków.
Przegl Lek. 2002;59(2):71-5.
Essential hypertension is one of the most important risk factors for cardiovascular diseases. Its pathophysiological mechanism is unknown. Recent data suggests that deformability and aggregation of red blood cells may play an important role in the regulation of blood rheology in hypertension. Simultaneously there are reports suggesting that antihypertensive effects of angiotensin converting enzyme inhibitors (ACEI) could be counteracted by high doses of aspirin. We postulate that these effects could be related to the changes in blood rheology. Accordingly we designed a study to evaluate the effect of low or high dose of aspirin on deformability and aggregability of red blood cells from patients with essential hypertension. Deformability and aggregability of red blood cells were measured by laser diffractometer (Rheodyn SSD, Myrenne GmbH) and computerized automatic aggregometer (MA1 Myrenne GmbH, Germany), respectively. The effects of aspirin on deformability and aggregation of red blood cells were studied ex vivo in whole blood from three groups of patients with essential hypertension (group I: 10 patients receiving placebo, group II: 23 patients receiving 75 mg/day p.o. aspirin for 3 days, and group III: 23 patients receiving 300 mg/day p.o. aspirin for 3 days). Subjects in all groups received the same combination of antihypertensive agents consisting of: one of ACEI (enalapril or perindopril), one of beta-antagonists (metoprolol or bisoprolol), and diuretic agent (indapamid). In patients receiving high dose of aspirin (300 mg/day) we observed that erythrocyte aggregability was 25% higher than in the placebo group (MEA = 25.8 +/- 6 SD, vs MEA = 20.6 +/- 3 SD, p < 0.05). Aspirin had no effects on deformability of erythrocytes or on arterial blood pressure. High doses of aspirin or possibly also other nonsteroidal anti-inflammatory drugs (NSAID) in patients receiving antihypertensive therapy can directly affect rheological properties of the blood due to the activation of red blood cell aggregation. Increased aggregation of red blood cells during antihypertensive therapy may be an important indicator of the worsening of organ perfusion.
原发性高血压是心血管疾病最重要的危险因素之一。其病理生理机制尚不清楚。最近的数据表明,红细胞的变形性和聚集性可能在高血压血液流变学调节中起重要作用。同时,有报道称血管紧张素转换酶抑制剂(ACEI)的降压作用可能会被高剂量阿司匹林抵消。我们推测这些作用可能与血液流变学的变化有关。因此,我们设计了一项研究来评估低剂量或高剂量阿司匹林对原发性高血压患者红细胞变形性和聚集性的影响。红细胞的变形性和聚集性分别通过激光衍射仪(Rheodyn SSD,Myrenne GmbH)和计算机自动凝集仪(MA1 Myrenne GmbH,德国)进行测量。在三组原发性高血压患者的全血中离体研究阿司匹林对红细胞变形性和聚集性的影响(第一组:10名接受安慰剂的患者,第二组:23名口服75毫克/天阿司匹林3天的患者,第三组:23名口服300毫克/天阿司匹林3天的患者)。所有组的受试者接受相同的降压药物组合,包括:一种ACEI(依那普利或培哚普利)、一种β受体拮抗剂(美托洛尔或比索洛尔)和利尿剂(吲达帕胺)。在接受高剂量阿司匹林(300毫克/天)的患者中,我们观察到红细胞聚集性比安慰剂组高25%(平均聚集度MEA = 25.8 +/- 6标准差,vs MEA = 20.6 +/- 3标准差,p < 0.05)。阿司匹林对红细胞变形性或动脉血压没有影响。接受降压治疗的患者服用高剂量阿司匹林或可能还有其他非甾体抗炎药(NSAID)会因激活红细胞聚集而直接影响血液的流变学特性。降压治疗期间红细胞聚集增加可能是器官灌注恶化的一个重要指标。